drugset / Trial / NCT00426816
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
RandomizedCrossoverTriple-blindTreatment
Summary
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
Timeline
- Start
- 2006-12
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SB-649868 | Small molecule | 10 mg | — |
| Subject | SB-649868 | Small molecule | 30 mg | — |
| Subject | SB-649868 | Small molecule | 60 mg | — |